Table 1 |
|||||
|
Data of patients with GD before methimazole therapy, after six months of therapy (prior to surgery) in non-toxic multinodular goiter and HT |
|||||
|
Untreated GD group Group A |
Group after six months of methimazole therapy Group A' |
Group with HT Group B |
Group with non-toxic multinodular goiter Group C |
P |
|
|
|
|||||
|
Age (years) |
15.4 ± 2.1 |
16.4 ± 3.3 |
16.8 ± 2.8 |
15.8 ± 1.8 |
NS, NS*, NS** |
|
|
|||||
|
n |
18 |
18 |
18 |
18 |
|
|
|
|||||
|
Weight (kg) |
57 ± 11.0 |
59 ± 7 |
63 ± 8 |
62 ± 7 |
NS, NS*, NS** |
|
|
|||||
|
Height (cm) |
166 ± 3 |
169 ± 1 |
170 ± 5 |
169 ± 7 |
NS, NS*, NS** |
|
|
|||||
|
BSA (m2) |
1.66 |
1.68 |
1.7 |
1.67 |
NS, NS*, NS** |
|
|
|||||
|
anti-TPO (IU/ml) |
1250 ± 350 |
650 ± 250 |
1550 ± 500 |
41.3 ± 38 |
p < 0.0001, p* < 0.01, p** < 0.001 |
|
|
|||||
|
anti-TG (IU/ml) |
630 ± 262 |
360 ± 40 |
820 ± 150 |
180 ± 86 |
p < 0.001, p* < 0.01, p** < 0.001 |
|
|
|||||
|
TRAb (U/l) |
> 5 positive |
> 3 positive |
(-) |
(-) |
|
|
|
|||||
|
fT4 (ng/dl) |
5.9 ± 2.0 |
2.04 ± 0.3 |
1.29 ± 0.2 |
1.1 ± 0.2 |
p < 0.001, NS*, NS** |
|
|
|||||
|
fT3 (ng/dl) |
8.85 ± 2.1 |
3.8 ± 0.5 |
3.64 ± 0.21 |
2.94 ± 0.21 |
p < 0.002, NS*, NS** |
|
|
|||||
|
TSH (μIU/ml) |
0.03 ± 0.01 |
1.3 ± 0.2 |
3.1 ± 0.5 |
2.9 ± 0.3 |
p < 0.001 p* < 0.01, NS** |
|
|
|||||
|
GD- Graves' disease HT- Hashimoto's thyroiditis NTMG-non-toxic multinodular goiter p, Statistical significance between group A and C; p*, statistical significance between group A' and C; p**, statistical significance between group B and C; X, standard deviation; NS, no statistical significance. |
|||||
|
Bossowski et al. Thyroid Research 2011 4:13 doi:10.1186/1756-6614-4-13 |
|||||
